Frontage’s Bioanalytical Team is highly experienced in developing, qualifying, and validating biomarker assays for Alzheimer's Disease. Our biomarker assay services provide accurate, reliable information for our partners.

A companion diagnostic is a predictive biomarker test, utilized to support dosing decision-making for patient stratification and treatment. It received global support and the market size is expected to double within the next 5 years. This webinar reviews the importance and regulatory success of companion diagnostic biomarker assays in currently approved drugs, as well as forecasting the trend and possible issues that might arise in the future. In addition, the outsourcing of companion diagnostic tests to a contract research lab will be discussed.

Biomarkers as indicators of biological and pathogenic processes have been used for decades to diagnose patients and prescribe treatment. In the past 10 years, however, they’ve substantially changed drug development practices. The demand for analyzing biomarkers in drug development has increased dramatically with the advancement of precision medicine. In the drug development context, biomarkers that are indicative of mechanism of action, target engagement, and clinical outcomes have been employed to assess both the safety and efficacy of an intervention. More specifically, biomarkers have been used either to select patients for clinical trials, to make go/no-go decisions, to support registration and label claims, or to treat patients.